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DEAR EDITOR, Mutations in the PSTPIP1 gene encoding proline-serine-threonine-phosphatase 
interactive protein 1 were first identified in an autosomal dominant syndrome called PAPA associated 
with pyogenic sterile arthritis, pyoderma gangrenosum (PG) and cystic acne.1,2  
We report a patient with an autoinflammatory syndrome called PSTPIP1-associated myeloid-related 
proteinemia inflammatory (PAMI) syndrome.3  
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A 23-year-old man had a 3-year-history of skin ulcerations. During childhood he exhibited anemia (81 
g/l), neutropenia (0,3 G/l), mild thrombocytopenia and hepatosplenomegaly. Presence of anemia and 
of recurrent infections prompted a bone marrow biopsy, which showed evidence for disturbed 
myelopoiesis beyond the promyelocytes/myelocytes level. From the age of 7 years, he developed 
relapsing sterile osteomyelitis affecting the left talus, tibia and fibula. In his adolescence, he suffered 
from relapsing sterile arthritis of one knee and elbow.  
On examination, the patient had nodulocystic acne on his face and back. On the right thigh, there was 
an ulceration of 5 x 7 cm in diameter, while two other ulcers of 7 x 12 cm and 6 x 10 cm were found 
on the left and right legs, respectively (Fig. 1). The periphery showed a purple halo with undermined 
borders or cribriform scarring. Light microscopy studies revealed diffuse neutrophilic dermal 
infiltration. Special stainings, microbiological examinations and cultures remained negative. The ESR 
was 55 mm/h and the C-reactive protein 68 mg/L. There was a microcytic anemia (114 g/l) and 
neutropenia (0,69 G/l). Renal and hepatic tests as well as immunoglobulin levels were unaltered. 
Search for antinuclear antibodies and rheumatoid factors was negative. A pathergy phenomenon was 
often observed at the site of blood tests. Suspecting PAPA syndrome, we sequenced the coding 
sequence of PSTPIP1.2 Genetic analyses identified a heterozygous pathogenic c.748G>A mutation 
predicted to result in the substitution of a highly conserved residue at position 250, E250K, of 
PSTPIP1. Since this same mutation was identified in PAMI syndrome,1 we measured the 
concentrations of serum zinc, S100A8/A9 (calprotectin) and S100A12 (calgranulin C). The latter 
were of 140 μmol/l (11-18 μmol/l), of 2’050’000 ng/ml (< 2’900 ng/ml) and 303’000 ng/ml (< 
75ng/ml), respectively. The patient was treated with prednisolone 1 mg/kg daily and topical 
tacrolimus with partial response after 20 weeks. To better control the ulcerations, the patient was 
given infliximab (5 mg/kg body weight) and prednisolone, 20 mg per day. This treatment was 
ineffective and stopped after 4 cycles. The patient was subsequently treated with monthly injections of 
canakinumab, 300 mg, with prednisone 20 mg daily. IL-1  inhibition showed no benefit and was 
cessated after three injections. Finally, injections of secukinumab, 300mg every two weeks with 
prednisone 20 mg daily resulted in a partial reduction of the ulcerations (Fig. 1c). These treatments 
did not improve the acne, which showed some response to oral isotretinoin only. All attempts to 
discontinue the corticosteroids resulted in exacerbation of PG. The patient was then also given 
ciclosporin 4 mg/kg daily with almost complete healing of the PG during the past 6 months (Fig. 1d) 
and good tolerance.  
In addition to PAPA syndrome, PSTPIP1 mutations have been associated with PG, acne and 
hidradenitis suppurativa with or without pyogenic arthritis.4,5 Isolated aseptic abdominal abscesses, 
pyogenic arthritis and osteolytic lesions have also been linked to PSTPIP1 variants (review table 
available upon request to the corresponding author).2-7 Recently, pathogenic de novo mutations in 
PSTPIP1 leading to the amino acid substitution E250K or pE257K have been linked to PAMI, a 
severe autoinflammatory syndrome characterized by pancytopenia, hepatosplenomegaly, acne and 
PG.2,3 Our patient had all features of PAPA. However, he had a history of systemic inflammation, 
pancytopenia, hepatosplenomegaly and pyogenic arthritis in childhood. He also exhibited significant 
hypercalprotectinaemia and hyperzincaemia that distinguish PAMI from PAPA syndrome.2 Our case 
had further episodes of osteomyelitis. The latter has been reported in PAMI but not in PAPA. In 
PAMI the response to either anti-IL-1 or anti-TNFα blockade is inconstant.2,3 In contrast, PAPA 
usually shows a good response to anti-IL-1 blockade.7 Our trial with a novel IL-17A antagonist, 
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secukinumab, showed only a partial effect. Only addition of ciclosporin possessing broad anti-
inflammatory properties resulted in benefit as reported in a case with the same PSTPIP1 mutation.8 
The inflammatory cascade triggered by PSTP1P1 defects seems to be affected by the type of 
mutations and their impact on PSTP1P1 function.2,3 Nevertheless, defects of other genes, such as 
nicastrin (NCSTN) may result in similar clinical inflammatory manifestations.7 
Our case illustrates the broad spectrum of phenotypes associated with PSTPIP1 mutations which 
variably affect over the years only one organ up to a severe autoinflammatory disorder, management 
of which remains challenging.  
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Figure Legend 
Fig 1. Clinical photographs of the patient with PSTPIP1-associated myeloid-related proteinemia 
inflammatory (PAMI) syndrome. (a) Nodulocystic acne affecting the face. (b) Pyoderma 
gangrenosum with typical features over the anterior aspect of the lower leg. (c) Partial response upon 
introduction of secukinumab. (d) Addition of ciclosporin resulted in clinical benefit with almost 
clearing of the ulcerations.  
 
 
 
 
 
 
